Avalo Therapeutics (AVTX) Assets (2014 - 2026)
Avalo Therapeutics' (AVTX) quarterly Assets came in at $99.9 million in Q1 2026, down 27.89% YoY from $138.5 million in Q1 2025, and down 14.23% on a QoQ basis from $116.5 million in Q4 2025.
Avalo Therapeutics (AVTX) Assets (2014 - 2026) Analysis & Trends
Avalo Therapeutics (AVTX) has 13 years of Assets data on file, last reported at $99.9 million in Q1 2026.
- Quarterly Assets fell 27.89% year-over-year to $99.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $99.9 million (down 27.89% YoY) and the FY2025 annual result came in at $116.5 million, down 22.74% from the prior year.
- Assets retreated to $99.9 million in Q1 2026, from $116.5 million in the prior quarter.
- In the past five years, Assets ranged from a high of $150.7 million in Q4 2024 to a low of $21.0 million in Q4 2023.
- A 5-year average of $80.1 million and a median of $98.5 million in 2024 frame the typical range for Assets.
- Annual changes were most pronounced in 2022 — Assets plunged 61.67% — and 2024, when it surged 618.01%.
- Tracing AVTX's Assets over 5 years: stood at $33.4 million in 2022, then sank by 37.08% to $21.0 million in 2023, then surged by 618.01% to $150.7 million in 2024, then slipped by 22.74% to $116.5 million in 2025, then fell by 14.23% to $99.9 million in 2026.
- The last three Assets figures came in at $99.9 million (Q1 2026), $116.5 million (Q4 2025), and $125.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - | 490.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 490.78 Mn |
| Mar 31, 2026 | 99.89 Mn |
| Dec 31, 2025 | 116.46 Mn |
| Sep 30, 2025 | 125.10 Mn |
| Jun 30, 2025 | 126.58 Mn |
| Mar 31, 2025 | 138.52 Mn |
| Dec 31, 2024 | 150.73 Mn |
| Sep 30, 2024 | 98.46 Mn |
| Jun 30, 2024 | 108.31 Mn |
| Mar 31, 2024 | 123.73 Mn |
| Dec 31, 2023 | 20.99 Mn |
| Sep 30, 2023 | 29.27 Mn |
| Jun 30, 2023 | 24.24 Mn |
| Mar 31, 2023 | 36.24 Mn |
| Dec 31, 2022 | 33.37 Mn |
| Sep 30, 2022 | 36.55 Mn |
| Jun 30, 2022 | 32.22 Mn |
| Mar 31, 2022 | 61.90 Mn |
| Dec 31, 2021 | 80.21 Mn |
| Sep 30, 2021 | 95.36 Mn |